Back at Work, Not Necessarily Recovered: Germany’s Return-to-Work Gap

A return-to-work date is easy to record. Whether someone can sustain that return is harder to measure. German research follows functioning beyond the first day back and questions whether more treatment spending necessarily delivers the expected benefit. For executives and family-business owners, recovery needs to describe the responsibilities they can sustain, not simply when they reappear at work.

Key findings

5.33 to 6.35: mean self-reported work ability before discharge and at six months in a paired German study group of 269 employees.

30 months: the broader study’s follow-up horizon. Returning to work was not treated as the last observation. [1]

Approximately 22% and 14%: depressive and anxiety symptoms above screening thresholds in RKI’s 2024 panel. A data-collection change limits comparison with the previous year. [2]

€3,484.29: additional annual cost in one workplace-psychotherapy evaluation. The estimated quality-of-life benefit remained uncertain. [4]

Work ability continued changing after discharge

The chart compares the same paired group. Higher scores indicate better self-reported work ability. Source: Sikora and colleagues, online publication February 2025, journal issue March 2026. [1]

The study enrolled 286 employees after treatment for common mental disorders and included interviews with 32 participants. Some had returned while their ability to sustain demands remained fragile.

The implication is to keep asking about functioning after re-entry. Attendance can be a milestone without being the final clinical outcome. The observed improvement does not establish which treatment component caused it.

The national symptom trend has a measurement break

RKI’s 2024 panel analysis included 27,102 participants. About 22% exceeded the PHQ-9 depressive-symptom threshold and about 14% exceeded the GAD-7 anxiety-symptom threshold. These are screening measures, not newly confirmed diagnoses. [2]

RKI cautioned that the apparent increase from the preceding year was substantially affected by moving from telephone interviews to online or paper collection. The earlier trend could not be conclusively extended across that change.

The depression and anxiety groups overlap. Adding the percentages would double-count people, while treating the method change as a sudden health deterioration would overstate what the comparison establishes.

Stress is not confined to senior roles

A June 2026 RKI panel publication reported elevated perceived stress in about 20% of respondents. Women, working-age adults, and people with lower or medium formal education were more frequently affected. Associations with coping strategies were observational. [3]

The findings do not establish that executives are uniquely burdened or that one coping strategy guarantees improvement. They support taking a person’s actual circumstances seriously rather than using job title or educational advantage as a health assessment.

Extra spending did not establish a clear gain in one evaluation

The quality-of-life interval includes no difference. Participants received eight intervention sessions on average. Source: Mulfinger and colleagues, March 1, 2026. [4]

This is one program evaluation, not a verdict that workplace therapy never helps. An uncertain benefit is not proof of identical outcomes in every circumstance.

It does create a useful accountability question: what extra benefit was measured rather than assumed from extra care? A treatment budget and a clinical result are separate observations.

Rehabilitation volume is not a recovery rate

Deutsche Rentenversicherung’s 2025 atlas reports more than one million medical rehabilitation services in 2024. Mental-health conditions accounted for about 22% of women’s and 13% of men’s medical rehabilitation indications. These are service shares, not population prevalence. [5]

The atlas also reports approximately 168,000 outpatient services in 2024 compared with 75,000 in 2006. That describes a change in provision, not proof that one setting produced better recovery.

For families comparing options, the next question is which patients improved, how that was assessed, and what happened after the formal program ended.

The largest absence cost is not a mental-health-only figure

BAuA estimated 881.5 million sickness-absence days in Germany in 2024, with production losses of €134 billion and lost gross value added of €227 billion. These estimates cover relevant sickness absence across conditions. They are alternative economic measures, not amounts to add together. [6]

Using the largest national cost under a mental-health headline without that qualifier would mislead. It is also not an invoice for an individual employer or a forecast of losses in a particular family business.

What affluent families should ask about return to work

A founder or owner-manager may return to responsibilities that differ from a defined employee role. The assessment should identify the decisions, hours, relationships, and support that matter in practice.

A prestigious title does not prove readiness to resume everything. A considered reduction in responsibilities is not automatically a failed recovery either.

Work ability should sit alongside symptoms, sleep, relationships, and the patient’s priorities. An employer’s interest in attendance should not replace the person’s own goals.

These are care-planning implications, not measured HNW effects. The cited research did not establish separate recovery rates for executives, founders, or family-business successors.

The plan after re-entry should be specific

This is a proposed discussion framework, not a validated return-to-work program or legal instruction. Employment and professional requirements need appropriate local advice.

A useful plan also explains what happens if the initial workload is not sustainable. Reassessment should be part of the pathway rather than a sign that the patient has disappointed the program.

Care abroad needs a German receiving pathway

A German resident considering treatment elsewhere should understand follow-up on return. A discharge summary is not confirmation that a local clinician has accepted responsibility or that appointments are available.

Agree the handover and check cross-border arrangements before travel. The family can assist with logistics without being left to reconcile clinical recommendations alone.

The question is not whether leaving Germany is inherently better or worse. Privacy or distance during treatment should be considered alongside the continuity of the whole pathway.

What the evidence cannot tell us

The work-ability change is observational. The RKI figures are screening results with a method transition. The FRIAA evaluation does not compare private residential care with every workplace intervention. None of the sources establishes an executive epidemic or a private-care advantage.

The bottom line

Re-entry is a milestone, not a complete recovery measure. A return date, treatment budget, and completed program do not describe the same outcome. Families should ask what the person can sustain after care and how that result will be followed.

For journalists

Key contrast: work ability improved after discharge in an observational cohort, while a separate program evaluation found higher cost without a clearly established quality-of-life gain.

Important caveat: these are different studies, not a single comparison of German treatment providers.

Suggested attribution: THE BALANCE analysis of published German mental-health and work-outcome evidence.

Methodology and sources

This narrative analysis separates symptom surveys, service activity, observed functioning, and economic evaluation. It retains the source periods and uncertainty. No provider ranking or new client-group estimate was calculated.

1. Sikora and colleagues. Work ability during return to work. Online February 6, 2025; issue March 2026.
2. RKI. Depressive and anxiety symptoms in the 2024 panel. December 2025.
3. RKI. Perceived stress and coping. June 17, 2026.
4. Mulfinger and colleagues. FRIAA cost-utility evaluation. March 1, 2026.
5. Deutsche Rentenversicherung. Rehabilitation Atlas 2025.
6. BAuA. Economic costs of sickness absence, 2024.